MediPaper @medipaper - Tumblr Blog

ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised

Venetoclax FDA approved for CLL and SLL

Ramucirumab FDA approved for hepatocellular carcinoma

FDA approves avelumab plus axitinib for renal cell carcinoma

T-DM1 FDA approved for early breast cancer

Ivosidenib FDA-approved as first-line treatment for AML patients with IDH1 mutation

Palbociclib approved for the treatment of male breast cancer

Atezolizumab +/- cobimetinib vs regorafenib for previously treated metastatic colorectal cancer (IMblaze370)

Happy Chinese New Year 2019

Trastuzumab-biosimilar Ontruzant® FDA approved in several indications

ERAS guidelines for antenatal and preoperative care in caesarean delivery

Cabozantinib FDA approved in HCC patients failing sorafenib

Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

Keytruda® FDA approved for recurrent and metastatic Merkel cell carcinoma

Calaspargase pegol-mknl (Asparlas®) FDA approved in paediatric and young adult acute lymphoblastic leukaemia (ALL) patients

It is thought that immune-checkpoint inhibitors could exacerbate chronic hepatitis B and C by enhancing T-cell cytotoxicity to viral antigens. The effects of PD-1, PD-L1 and CTLA4 inhibitors on HBV and HCV have largely been unreported. Most studies with I-O drugs excluded patients with chronic viral hepatitis. However, recent trials investigating I-O in HCC included subjects who were known hepatitis B and C carriers.

I-O in Special Populations: Chronic Viral Hepatitis Carriers https://medipr.org/2QwU1ps #BMS #Bristol-MyersSquibb #CTLA4 #HBV #HCV #hepatitis #I-O #nivolumab #Opdivo #PD-1

Trending Blogs

Recently Viewed Blogs

MediPaper